Form ARS Spero Therapeutics, Inc. For: Dec 31
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves GSK and Spero's oral carbapenem antibiotic Utebzi
- EP3M Summit 2026 Brings Together Biopharma Leaders to Advance Portfolio Strategy, Decision Intelligence, and Innovation Portfolio Management
- First Trust Expands Its Autocallable Barrier & Income ETFs with ACYQ
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
